Skip to content
RDL Network logo
15287 Comparisons of symptom-free and sign-free status among patients with moderate to severe plaque psoriasis treated with guselkumab or adalimumab: Results from VOYAGE 1 — Christopher Em Griffiths (2020) | RDL Network